Search result for 'drug manufacturing'

The Indian Pharmaceutical Alliance refutes a study claiming Indian generic drugs have higher adverse events, stating quality is not region-dependent and meets global standards.

The USFDA issued a warning letter to Granules India for violations at its Telangana plant, including contamination issues, inadequate maintenance, and improper record-keeping.

India witnessed a significant rise in drug recalls in 2023-24, with 1,394 batches failing quality tests. The Minister of State for Health revealed the data, highlighting concerns over drug quality.

USFDA issued a warning letter to Sun Pharma for failing to adequately clean and maintain equipment at its Dadra facility, citing violations of Current Good Manufacturing Practice (CGMP)...

A court has issued an interim stay on the suspension of manufacturing licences for 14 Patanjali drugs, following a preliminary inquiry report that found the suspension order to be illegal.

MedPlus Health Services plans to increase its revenue from in-house branded medications to 50-60% in the next 3 years, following the successful model of US pharma giants like Walgreens and CVS.

India's interim budget focuses on strengthening the healthcare sector, promoting bulk drug manufacturing, and enhancing nutrition programs. The allocation of Rs 90,658.63 crore for health and the...

Recalls and infections highlight the need for increased FDA oversight of eyedrop manufacturing, including mandatory recalls and pre-shipment inspections.

India's pharmaceutical sector is projected to reach USD 130 billion by 2030, driven by expanding market opportunities and rising global demand. Experts highlight the industry's growth trajectory...